ஆலோசனை தலைமை மருத்துவ அதிகாரி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆலோசனை தலைமை மருத்துவ அதிகாரி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆலோசனை தலைமை மருத்துவ அதிகாரி Today - Breaking & Trending Today

GT Biopharma Reports First Quarter 2021 Results

GT Biopharma Reports First Quarter 2021 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Anthonyj Cataldo , Jeffreys Miller , Cytovance Biologics , Beverly Hills , Gregory Berk , Rajesh Shrotriya , Michael Breen , Exchange Commission , Development Expenses , Leadership Team , Company Board Of Directors , Source Gt Biopharma Inc , University Of Minnesota , Gt Biopharma Inc , Chief Executive , Interim Results , High Risk Myelodysplastic Syndromes , Relapsed Acute Myeloid Leukemia , Phasei Portion , Trial Design , Public Offering , Successful Nasdaq Listing , Key Appointments , Chief Medical Officer , Consulting Chief Medical Officer , Consulting Chief Scientific ,

GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer

Share this article
Share this article
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma s Board since November 2020, and resigns that post in conjunction with his appointment.
The Company is also pleased to announce that Jeffrey S. Miller, M.D., who has supported GT Biopharma as the Company s Consulting Chief Medical Officer since August 2019, will become the Company s Consulting Chief Scientific Officer. Dr. Miller, with his colleagues at the University of Minnesota, is the inventor of the novel TriKE™ technology platform. Dr. Miller will continue his leadership role with respect to ....

Julie Seidel , Jeff Miller , Gregory Berk , Susan Roush , Jeffreys Miller , Anthonyj Cataldo , David Castaneda , Beverly Hills , Prnewswire Gt Biopharma Inc , Board Member Of Sideris Pharmaceuticals , Global Clinical Development At Abraxis Bioscience , Stern Investor Relations Inc , Source Gt Biopharma Inc , Company Consulting , Exchange Commission , Weill Medical College Of Cornell University , University Of Minnesota , Gt Biopharma Inc , Case Western Reserve University , Chief Medical , Consulting Chief Medical Officer , Consulting Chief Scientific , Chief Medical Officer , Chief Scientific , Chief Executive , Board Member ,

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update

Published: Apr 19, 2021

BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020.
2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the beginning of 2021. The emerging data from our GTB-3550 TriKE™ program in hematological malignancies, MDS and AML, are encouraging in both safety and efficacy profiles. The ongoing data profile has demonstrated significant differences from all other NK cell therapies and NK engager companies, making TriKE™ a monotherapy, off-the-shelf platform therapeutic. TriKE™ exerts ....

United States , Samir Taneja , Julie Seidel , Cytovance Biologics , Michael Handelman , Philip Werthman , Rajesh Shrotriya , Greg Berk , Susan Roush , Jeffreys Miller , Anthonyj Cataldo , David Castaneda , Beverly Hills , Michael Breen , Brucej Wendel , Iovance Biotherapeutics , Hospital Harvard Medical School , Company Scientific , Stern Investor Relations Inc , Source Gt Biopharma Inc , Exchange Commission , American Society Of Hematology , Development Expenses , University Of Wisconsin , Leadership Team , University Of Minnesota ,

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Samir Taneja , Julie Seidel , Cytovance Biologics , Michael Handelman , Philip Werthman , Rajesh Shrotriya , Greg Berk , Susan Roush , Jeffreys Miller , Anthonyj Cataldo , David Castaneda , Beverly Hills , Michael Breen , Brucej Wendel , Iovance Biotherapeutics , Hospital Harvard Medical School , Company Scientific , Stern Investor Relations Inc , Source Gt Biopharma Inc , Exchange Commission , American Society Of Hematology , Development Expenses , University Of Wisconsin , Leadership Team , University Of Minnesota ,

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , Julie Seidel , Anthony Cataldo , Jeffreys Miller , David Castaneda , Beverly Hills , Susan Roush , Prnewswire Gt Biopharma Inc , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Masonic Cancer Center , Deputy Director , Consulting Chief Medical Officer , Innate Killer Summit , Off The Shelf Strategies , Increase Activity , Bone Marrow Blast , Allogenic Cell Therapy , Bone Marrow Blast Levels , Cytokine Release Syndrome , Maximum Tolerated Dose , Clin Cancer ,